Table 5 Interaction analysis between the polymorphisms TP53 rs17878362 (16 bp Del/Ins) and TP53 rs1042522 (G > C) and clinical manifestations (serositis and neuropsychiatric disorders) of SLE patients
From: TP53 and p21 (CDKN1A) polymorphisms and the risk of systemic lupus erythematosus
Polymorphism | Genetic model | Serositis | Neuropsychiatric disorders | ||||
|---|---|---|---|---|---|---|---|
Yes n | No n | OR (CI 95%) | Yes n | No n | OR (CI 95%) | ||
TP53 rs17878362 16 bp Del/Ins | A1A1 | 35 | 39 | 1.00 | 13 | 61 | 1.00 |
A1A2 | 21 | 10 | 2.34 (0.97–5.64) | 8 | 24 | 1.56 (0.58–4.25) | |
A2A2 | 0 | 8 | NA | 4 | 4 | 4.69 (1.04–21.24)b | |
A1A1 | 35 | 39 | 1.00 | 13 | 61 | 1.00 | |
A1A2 + A2A2 | 21 | 18 | 1.30 (0.60–2.83) | 12 | 28 | 2.01 (0.81–4.96) | |
A2A2 | 0 | 8 | 1.00 | 4 | 4 | 1.00 | |
A1A1 + A1A2 | 56 | 49 | NA | 21 | 85 | 4.05 (0.93–17.53) | |
A1A2 | 21 | 10 | 1.00 | 8 | 24 | 1.00 | |
A1A1 + A2A2 | 35 | 47 | 2.82 (1.18–6.74)a | 17 | 65 | 1.27 (0.49–3.34) | |
A1 | 91 | 88 | 1.00 | 34 | 146 | 1.00 | |
A2 | 21 | 26 | 0.78 (0.41–1.49) | 16 | 32 | 2.15 (1.06–4.35)c | |
TP53 rs1042522 G > C | GG | 19 | 18 | 1.00 | 4 | 32 | 1.00 |
GC | 31 | 26 | 1.13 (0.49–2.59) | 13 | 46 | 2.26 (0.68–7.57) | |
CC | 6 | 13 | 0.44 (0.14–1.40) | 8 | 11 | 5.82 (1.46–23.17)d | |
GG | 19 | 18 | 1.00 | 4 | 32 | 1.00 | |
GC + CC | 37 | 39 | 0.90 (0.41–1.97) | 21 | 57 | 2.95 (0.93–9.34) | |
GG + GC | 50 | 44 | 1.00 | 17 | 78 | 1.00 | |
CC | 6 | 13 | 0.41 (0.14–1.16) | 8 | 11 | 3.34 (1.17–9.55)e | |
GG + CC | 25 | 31 | 1.00 | 12 | 43 | 1.00 | |
GC | 31 | 26 | 1.48 (0.70–3.10) | 13 | 46 | 1.01 (0.42–2.46) | |
G | 69 | 62 | 1.00 | 21 | 110 | 1.00 | |
C | 43 | 52 | 0.74 (0.44–1.26) | 29 | 68 | 2.23 (1.18–4.29)f | |